Editor-in-Chief:
ARUN SETHI, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada

Managing Editor:
J.G. DELINASIOS, International Institute of Anticancer Research (IIAR), Kapandriti, Attiki, Greece

Editorial Board
L. A. Aaltonen, Helsinki, Finland
R. Abagyan, La Jolla, CA, USA
F. Ahmed, Greenville, NC, USA
S. Antonarakis, Geneva, Switzerland
D.-T. Bau, Taiwan, ROC
M. R. Chance, Cleveland, OH, USA
A. M. Chinnaiyan, Ann Arbor, MI, USA
B. F. C. Clark, Aarhus, Denmark
R. Clarke, Washington, DC, USA
N. E. Davidson, Pittsburgh, PA, USA
I. Dunham, Cambridge, UK
T. Effertth, Muenster, Germany
J. A. Fernandez-Pol, Chesterfield, MO, USA
C. N. Fors, New York, NY, USA
M. Fountoulakis, Athens, Greece
D. S. Gerhard, Bethesda, MD, USA
T.R. Golub, Cambridge, MA, USA
J. Gordon, Philadelphia, PA, USA
J. W. Gray, Portland, OR, USA
B. B. Haab, Grand Rapids, MI, USA
C.-H. Heid, Uppsala, Sweden
J. D. Hohelsel, Heidelberg, Germany
R. P. Huang, Norcross, GA, USA
T. H. M. Huang, San Antonio, TX, USA
S. C. Jianwar, New York, NY, USA
V. C. Jordan, Washington, DC, USA
J. Ju, Stoney Brook, NY, USA
A. Kallioniemi, Tampere, Finland
O. P. Kallioniemi, Turku, Finland
K. Khalili, Philadelphia, PA, USA
D. G. Kieback, Riesa (Dresden), Germany
S. D. Kottaridis, Athens, Greece
B. Leyland-Jones, Sioux Falls, SD, USA
P. Lichter, Heidelberg, Germany
A. Lindblom, Stockholm, Sweden
G. Lubec, Vienna, Austria
J. Lyons-Weiler, Pittsburgh, PA, USA
P. J. McCormick, Rensselaer, NY, USA
J. D. Minna, Dallas, TX, USA
F. Mitelman, Lund, Sweden
P. Nelson, Seattle, WA, USA
C. Nicot, Kansas City, KS, USA
L. O’Driscoll, Dublin, Ireland
I. Pastan, Bethesda, MD, USA
C. D. Platsoucas, Norfolk, VA, USA
J. Quackenbush, Boston, MA, USA
J. S. Rader, Milwaukee, WI, USA
A. Raouf, Winnipeg, MB, Canada
G. Rasty, Toronto, ON, Canada
G. Rechavi, Tel-Hashomer, Israel
R. H. Reeves, Baltimore, MD, USA
K. L. Reichelt, Oslo, Norway
T. Ried, Bethesda, MD, USA
G. Rimbach, Kiel, Germany
K. D. Rodland, Richland, WA, USA
Y. Sakaki, Toyohashi, Aichi, Japan
C. Sansom, London, UK
N. A. Saunders, Queensland, Australia
B.W. Schäfer, Zurich, Switzerland
J. Schneider, Madrid, Spain
O. J. Semmes, London, UK
G. V. Sherbet, Newcastle-upon-Tyne, UK
K. K. Singh, Birmingham, AL, USA
S. Smith, Duarte, CA, USA
J. C. Srefford, Southampton, UK
J. M. Trent, Phoenix, AZ, USA
G. Tsangaris, Athens, Greece
L.-C. Tsui, Hong Kong, Hong Kong
G. F. Vande Woude, Grand Rapids, MI, USA
D. K. Watson, Charleston, SC, USA
A. T. Yeung, Philadelphia, PA, USA
H. Zhang, New Haven, CT, USA

Editorial Office: International Institute of Anticancer Research
1st km Kapandritiou-Kalamou Rd.,
P.O. Box 22, Kapandriti, Attiki 19014, Greece.
Tel: +30 22950 52945, Fax: +30 22950 53389
E-mails:
journals@iiar-anticancer.org (Editorial Office)
editor@iiar-anticancer.org (Managing Editor)
www.iiar-anticancer.org
http://cgp.iiarjournals.org

Front cover photograph: Figure 4B, page 100, this issue.

Copyright© 2013, International Institute of Anticancer Research
(Dr. John G. Delinassios), All rights reserved
CANCER GENOMICS & PROTEOMICS

Print ISSN (2004-2012): 1109-6535
Online ISSN: 1790-6245

VOLUME 10, No 3
2013
Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services:

- PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE; Compendex, GEOBASE; EMBiology; FLUIDEX; Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; Science Citation Index Expanded (Web of Science); Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office:
International Institute of Anticancer Research
1st km Kapandritiou-Kalamou Road,
P.O. Box 22, Kapandriti, Attiki, 19014, Greece.
Tel: +30 22950 52945, Fax: +30 22950 53389
e-mail: journals@iiar-anticancer.org; Web: www.iiar-anticancer.org; www.cgp.iiarjournals.org

Manuscripts and correspondence, should be addressed to: Dr. John G. Delinesios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca
Contents


Proteomic Analysis of Normal Murine Brain Parts. V.K. TARASLIA, A. KOUSKOUKIS, A.K. ANAGNOSTOPOULOS, D.J. STRAVOPODIS, L.H. MARGARITIS, G.TH. TSANGARIS (Athens, Greece) .................................................................................................................................................. 125
Instructions to Authors 2013

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) rational anticancer drug design and drug development. CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

The principal aim of CGP is to provide for the prompt online publication of original works of high quality, generally within 1-2 months of final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal (print or online), and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to CGP will be subject to peer-review by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are urgently treated with absolute confidence, with access restricted to the Editor-in-Chief, the Managing Editor, the journals’ secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts in terms of grammar and style.

The Editors and Publishers of CGP accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

Open Access Policy. CGP appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of Euro 700.00 for articles up to 6 online pages (including figures and tables). Each additional excess page will be charged Euro 50.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. CGP online will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and HTML files of all articles published in CGP are the property of the publisher.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all the essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

Manuscripts. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Color will not be charged.
Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'ISRCTN'). Please note that there is no space between the prefix 'ISRCTN' and the number. Example: ISRCTN47956475. For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Manuscripts may be submitted online (http://www.iiar-anticancer.org/submission/login.php), via e-mail (journals@iiar-anticancer.org), or by mail (3 complete copies plus, USB stick, DVD, CD or floppy disk) to the Editorial Office.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389. E-mails: Editorial Office: journals@iiar-anticancer.org. Managing Editor: editor@iiar-anticancer.org

Galley Proofs. Galley proofs will be sent by e-mail to the corresponding Author. Corrections of galley proofs should be limited to typographical errors.

Copyright© 2013, IIAR (J.G. Delinasios)